Skip to main content
SpringerLink
Log in

Gastrointestinal stromal tumors: Recommendations on diagnosis, therapy and follow-up care in Austria

Gastrointestinale Stromatumoren: Diagnose-, Behandlungs- und Nachsorgepfad für Österreich

  • Consensus report
  • Published:
Wiener klinische Wochenschrift Aims and scope Submit manuscript

Zusammenfassung

Interdisziplinäre Behandlung von gastrointestinalen Stromatumoren (GIST) ist Grundvoraussetzung für eine adäquate Behandlung dieser seltenen Tumorentität. Österreichische Vertreter der Fachdisziplinen Onkologie, Chirurgie, Pathologie, Radiologie und Gastroenterologie verfassten dieses Manuskript konsensuell. Anhand der bei der Manuskripterstellung verfügbaren und publizierten Fachliteratur wurden Leitlinien und Empfehlungen für Diagnose, Therapie und Kontrolle von GIST Patienten in Österreich erstellt.

Summary

Adequate treatment of gastrointestinal stromal tumors (GISTs) is linked to an interdisciplinary treatment approach. Austrian representatives of medical oncology, surgery, pathology, radiology and gastroenterology have issued this consensus manuscript within the context of currently available and published literature. The paper contains guidelines and recommendations for diagnosis, therapy and follow-up of GIST patients in Austria.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Thomas RM, Sobin LH (1995) Gastrointestinal cancer. Cancer 75 [Suppl 1]: 154–170

    Article  CAS  PubMed  Google Scholar 

  • Miettinen M, Lasota J (2001) Gastrointestinal stromal tumors – definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 438: 1–12

    Article  CAS  PubMed  Google Scholar 

  • Nilsson B, Bümming P, Meis-Kindblom JM, Odén A, Dortok A, Gustavsson B, et al (2005) Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era – a population-based study in western Sweden. Cancer 103: 821–829

    Article  PubMed  Google Scholar 

  • Gustafsson BI, Siddique L, Chan A, Dong M, Drozdov I, Kidd M, et al (2008) Uncommon cancers of the small intestine, appendix and colon: an analysis of SEER 1973–2004, and current diagnosis and therapy. Int J Oncol 33: 1121–1131

    PubMed  Google Scholar 

  • Miettinen M, Lasota J, Sobin LH (2005) Gastrointestinal stromal tumor of the stomach in children and young adults: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases with long-term follow-up and review of the literature. Am J Surg Pathol 29: 1373–1381

    Article  PubMed  Google Scholar 

  • Antonescu CR (2006) Gastrointestinal stromal tumor (GIST) pathogenesis, familial GIST, and animal models. Semin Diagn Pathol 23: 63–69

    Article  PubMed  Google Scholar 

  • Miettinen M, Fetsch JF, Sobin LH, Lasota J (2006) Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases. Am J Surg Pathol 30: 90–96

    Article  PubMed  Google Scholar 

  • Corless CL, Fletcher JA, Heinrich MC (2004) Biology of gastrointestinal stromal tumors. J Clin Oncol 22: 3813–3825

    Article  CAS  PubMed  Google Scholar 

  • Agaimy A, Wünsch PH, Hofstaedter F, Blaszyk H, Rümmele P, Gaumann A, et al (2007) Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol 31: 113–120

    Article  PubMed  Google Scholar 

  • Kawanowa K, Sakuma Y, Sakurai S, Hishima T, Iwasaki Y, Saito K, et al (2006) High incidence of microscopic gastrointestinal stromal tumors in the stomach. Hum Pathol 37: 1527–1535

    Article  PubMed  Google Scholar 

  • Roberts PJ, Eisenberg B (2002) Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease. Eur J Cancer 38 [Suppl 5]: S37–S38

    Article  PubMed  Google Scholar 

  • Agaimy A, Wünsch PH, Sobin LH, Lasota J, Miettinen M (2006) Occurrence of other malignancies in patients with gastrointestinal stromal tumors. Semin Diagn Pathol 23: 120–129

    Article  PubMed  Google Scholar 

  • Hirota S, Isozaki K (2006) Pathology of gastrointestinal stromal tumors. Pathol Int 56: 1–9

    Article  CAS  PubMed  Google Scholar 

  • Montemurro M, Dirnhofer S, Borner M, Burkhard R, Demartines N, Furrer M, et al (2008) Diagnose und Behandlung von GIST in der Schweiz. Schweizer Med Forum 8: 544–549

    Google Scholar 

  • Wardelmann E, Büttner R, Merkelbach-Bruse S, Schildhaus HU (2007) Mutation analysis of GIST: increasing significance for risk assessment and effective targeted therapy. Virchows Arch 451: 743–749

    Article  PubMed  Google Scholar 

  • Liegl B, Hornick JL, Corless CL, Fletcher CD (2009) Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes. Am J Surg Pathol 33: 437–446

    Article  PubMed  Google Scholar 

  • Dow N, Giblen G, Sobin LH, Miettinen M (2006) Gastrointestinal stromal tumors: differential diagnosis. Semin Diagn Pathol 23: 111–119

    Article  PubMed  Google Scholar 

  • Antonescu CR (2008) Targeted therapy of cancer: new roles for pathologists in identifying GISTs and other sarcomas. Mod Pathol 21 [Suppl 2]: S31–S36

    Article  CAS  PubMed  Google Scholar 

  • Corless CL, Heinrich MC (2008) Molecular pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol 3: 557–586

    Article  CAS  PubMed  Google Scholar 

  • Miettinen M, Sobin LH, Lasota J (2005) Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 29: 52–68

    Article  PubMed  Google Scholar 

  • Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al (2002) Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33: 459–465

    Article  PubMed  Google Scholar 

  • Miettinen M, Lasota J (2006) Gastrointestinal stromal tumors: pathology and prognosis at different sites, and differential diagnosis. Semin Diagn Pathol 23: 70–83

    Article  PubMed  Google Scholar 

  • Joensuu H (2008) Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 39: 1411–1419

    Article  PubMed  Google Scholar 

  • Katenkamp D, Katenkamp K (2008) Gastrointestinale Stromatumoren. Diagnose und Malignitätseinschätzung. Chirurg 79: 625–629

    Article  CAS  PubMed  Google Scholar 

  • Akahoshi K, Sumida Y, Matsui N, Oya M, Akinaga R, Kubokawa M, et al (2007) Preoperative diagnosis of gastrointestinal stromal tumor by endoscopic ultrasound-guided fine-needle aspiration. World J Gastroenterol 13: 2077–2082

    Article  PubMed  PubMed Central  Google Scholar 

  • Kingham TP, DeMatteo RP (2009) Multidisciplinary treatment of gastrointestinal stromal tumors. Surg Clin North Am 89: 217–233

    Article  PubMed  Google Scholar 

  • Raut CP, Ashley SW (2008) How I do it: Surgical management of gastrointestinal stromal tumors. J Gastrointest Surg 12: 1592–1599

    Article  PubMed  Google Scholar 

  • Langer C, Schüler P, Becker H, Liersch T (2008) Gastrointestinale Stromatumore aus chirurgischer Sicht. Chirurg 79: 644–649

    Article  CAS  PubMed  Google Scholar 

  • Otani Y, Furukawa T, Yoshida M, Saikawa Y, Wada N, Ueda M, et al (2006) Operative indications for relatively small (2–5 cm) gastrointestinal stromal tumor of the stomach based on analysis of 60 operated cases. Surgery 139: 484–492

    Article  PubMed  Google Scholar 

  • Pitsinis V, Khan AZ, Cranshaw I, Allum WH (2007) Single center experience of laparoscopic vs. open resection for gastrointestinal stromal tumors of the stomach. Hepatogastroenterology 54: 606–608

    CAS  PubMed  Google Scholar 

  • Alam I, Kheradmand F, Alam S, Jamil A, Wilson I, Hurley M (2007) Laparoscopic management of acutely presenting gastrointestinal stromal tumors: a study of 9 cases and review of literature. J Laparoendosc Adv Surg Tech A 17: 626–633

    Article  PubMed  Google Scholar 

  • Privette A, McCahill L, Borrazzo E, Single RM, Zubarik R (2008) Laparoscopic approaches to resection of suspected gastric gastrointestinal stromal tumors based on tumor location. Surg Endosc 22: 487–494

    Article  CAS  PubMed  Google Scholar 

  • Catena F, Di Battista M, Fusaroli P, Ansaloni L, Di Scioscio V, Santini D, et al (2008) Laparoscopic treatment of gastric GIST: report of 21 cases and literature review. J Gastrointest Surg 12: 561–568

    Article  PubMed  Google Scholar 

  • Sexton JA, Pierce RA, Halpin VJ, Eagon JC, Hawkins WG, Linehan DC, et al (2008) Laparoscopic gastric resection for gastrointestinal stromal tumors. Surg Endosc 22: 2583–2587

    Article  PubMed  Google Scholar 

  • Miettinen M, Sobin LH, Lasota J (2005) Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 29: 52–68

    Article  PubMed  Google Scholar 

  • Andtbacka RH, Ng CS, Scaife CL, Cormier JN, Hunt KK, Pisters PW, et al (2007) Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol 14: 14–24

    Article  PubMed  Google Scholar 

  • Eisenberg BL, Harris J, Blanke CD, Demetri GD, Heinrich MC, Watson JC, et al (2009) Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol 99: 42–47

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Heinrich MC, Owzar K, Corless CI, Hollis D, Borden EC, Fletcher CDM, et al (2008) Correlation of kinase genotype and clinical outcome in the North American Intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 26: 5360–5367

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, et al (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21: 4342–4349

    Article  CAS  PubMed  Google Scholar 

  • Van den Abbeele AD (2008) The lessons of GIST – PET and PET/CT: a new paradigm for imaging. Oncologist 13 [Suppl 2]: 8–13

    Article  PubMed  Google Scholar 

  • Sym SJ, Ryu MH, Lee JL, Chang HM, Kim TW, Kim HC, et al (2008) Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs). J Surg Oncol 98: 27–33

    Article  PubMed  Google Scholar 

  • Nilsson B, Sjölund K, Kindblom LG, Meis-Kindblom JM, Bümming P, Nilsson O, et al (2007) Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumors (GIST). Br J Cancer 96: 1656–1658

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • De Matteo RP, Owzar K, Antonescu CR, Maki R, Demetri GD, McCarter M, et al (2008) Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: The U.S. Intergroup phase II trial ACOSOG Z9000. Gastrointestinal Cancers Symposium: Abstract 8

  • DeMatteo R, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, et al (2009) Adjuvant imatinib mesylate after resection of localised primary gastrointestinal stromal tumor: a randomised, double-blind, placebo-controlled trial. Lancet 373: 1097–104

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Blay JY, Le Cesne A, Ray-Coquard I, Bui B, Duffaud F, Delbaldo C, et al (2007) Prospective multicentric randomized phase III study of imatinib in patients with advanced GIST comparing interruption vs. continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 25: 1107–1113

    Article  CAS  PubMed  Google Scholar 

  • Scandinavian Sarcoma Group: Study comparing 12 months versus 36 months of imatinib in the treatment of gastrointestinal stromal tumor (GIST); www.clinicaltrials.gov/ct2/show/NCT00116935?term=SSGXVIII&rank=1

  • European Organization for Research and Treatment of Cancer: imatinib mesylate or observation only in treating patients who have undergone surgery for localized gastrointestinal stromal tumor; www.clinicaltrials.gov/ct2/show/NCT00103168?term=EORTC+62024&rank=1

  • Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, et al (2000) Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295: 139–145

    CAS  PubMed  Google Scholar 

  • Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ (2000) Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96: 925–932

    CAS  PubMed  Google Scholar 

  • Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347: 472–480

    Article  CAS  PubMed  Google Scholar 

  • Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, et al (2008) Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26: 620–625

    Article  CAS  PubMed  Google Scholar 

  • Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, et al (2008) Phase III randomized, inter-group trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyroine kinase: S0033. J Clin Oncol 26: 626–632

    Article  CAS  PubMed  Google Scholar 

  • Verweij J, Casali PG, Zalcberg J, Le Cesne A, Reichardt P, Blay JY, et al (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364: 1127–1134

    Article  CAS  PubMed  Google Scholar 

  • Van Glabbeke MM, Owzar K, Rankin C, Simes J, Crowley J, GIST Meta-analysis Group (MetaGIST) (2007) Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): a meta-analysis based on 1640 patients. JCO 25 (18S): 10004

  • Debiec-Rychter M, Sciot R, Le Cescne A, Schlemmer M, Hohenberger P, van Oosterom AT, et al (2006) KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42: 1093–1103

    Article  CAS  PubMed  Google Scholar 

  • Demetri GD, Joensuu H (2008) Systemic treatment of patients with GIST: current status and future opportunities. Eur J Cancer 6: 1–14

    Article  CAS  Google Scholar 

  • Zalcberg JR, Verweij J, Casali PG, Le Cesne A, Reichardt P, Blay JY, et al (2005) Outcome of patients with advanced GIST crossing over to a daily Imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 41: 1751–1757

    Article  CAS  PubMed  Google Scholar 

  • Patel S, Zalcberg JR (2008) Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: lessons from the phase 3 trials. Eur J Cancer 44: 501–509

    Article  CAS  PubMed  Google Scholar 

  • Demetri GD, Wang Y, Wehrle E, Racine A, Nikolova Z, Blanke CD, et al (2009) Imatinib plasma levels correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol 27: 3141–3147

    Article  CAS  PubMed  Google Scholar 

  • Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368: 1329–1338

    Article  CAS  PubMed  Google Scholar 

  • George S, Blay JY, Casali PG, Le Cesne A, Stephanson P, Deprimo SE, et al (2009) Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 45: 1959–1968

    Article  CAS  PubMed  Google Scholar 

  • Rutkowski P, Symonides M, Zdzienicki M, Siedlecki JA (2008) Developments in targeted therapy of advanced gastrointestinal stromal tumors. Recent Pat Anticancer Drug Discov 3: 88–99

    Article  CAS  PubMed  Google Scholar 

  • Reichardt P (2008) Novel approaches to imatinib- and sunitinib-resistant GIST. Curr Oncol Rep 10: 344–349

    Article  CAS  PubMed  Google Scholar 

  • Cassier PA, Dufresne A, Arifi S, El Sayadi H, Ray-Coquard I, Bringuier PP, et al (2008) Novel approaches to gastrointestinal stromal tumors resistant to imatinib and sunitinib. Curr Gastroenterol Rep 10: 555–561

    Article  PubMed  Google Scholar 

  • Nilsson B, Nilsson O, Ahlmann H (2009) Treatment of gastrointestinal stromal tumours: imatinib, sunitinib – and then? Exp Opin Investig Drugs 18: 457–468

    Article  CAS  Google Scholar 

  • Casali PG, Jost L, Reichardt P, Schlemmer M, Blay JY; ESMO Guidelines Working Group (2008) Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 19 [Suppl 2]: ii35-8

    PubMed  Google Scholar 

  • Pantaleo MA, Di Battista M, Catena F, Astorino M, Saponara M, Di Scioscio V, et al (2008) Surgical debulking of gastrointestinal stromal tumors: is it a reasonable option after second-line treatment with sunitinib? J Cancer Res Clin Oncol 134: 625–630

    Article  CAS  PubMed  Google Scholar 

  • Ruka W, Rutkowski P, Szawlowski A, Nowecki Z, Debiec-Rychter M, Grzesiakowska U, et al (2009) Surgical resection of residual disease in initially inoperable imatinib-resistant/intolerant gastrointestinal stromal tumor treated with sunitinib. Eur J Surg Oncol 35: 87–91

    Article  CAS  PubMed  Google Scholar 

  • NCCN Clinical Practice Guidelines in Oncology, Soft Tissue Sarcome, v.1.2009; www.nccn.org

  • Sleijfer S, Wiemer E, Seynaeve C, Verweij J (2007) Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: a basis for novel approaches and individualization of treatment. Oncologist 12: 719–726

    Article  CAS  PubMed  Google Scholar 

  • Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, et al (2008) Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 26: 5352–5359

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, et al (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25: 1753–1759

    Article  PubMed  Google Scholar 

  • Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL, et al (2007) We should desist using RECIST, at least in GIST. J Clin Oncol 25: 1760–1764

    Article  PubMed  Google Scholar 

  • Casali PG, Jost L, Reichardt P, Schlemmer M, Blay JY; ESMO Guidelines Working Group (2009) Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20 [Suppl 4]: iv64–67

    Google Scholar 

  • Demetri GD, Benjamin RS, Blanke CD, Blay JY, Casali P, Choi H, et al (2007) NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST) – update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 5 [Suppl 2]: S1–S29

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Division of Oncology, Department of Internal Medicine, Medical University Graz, Graz, Austria

    Ferdinand Ploner & Thomas Brodowicz

  2. Clinical Division of General Surgery, Department of Surgery, Medical University Vienna – General Hospital, Vienna, Austria

    Johannes Zacherl

  3. Institute of Clinical Pathology, Medical University Vienna – General Hospital, Vienna, Austria

    Friedrich Wrba

  4. Department of General Medicine, Hospital Wiener Neustadt, Wiener Neustadt, Austria

    Friedrich Längle & Evelyne Bareck

  5. Department of Internal Medicine 1, Medical University Innsbruck, Innsbruck, Austria

    Wolfgang Eisterer

  6. Department of Internal Medicine 4, Hospital Wels – Grieskirchen, Austria

    Thomas Kühr

  7. Department of Radiology, Hospital Göttlicher Heiland, Vienna, Austria

    Wolfgang Schima

  8. Clinical Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University Vienna – General Hospital, Vienna, Austria

    Michael Häfner

Authors
  1. Ferdinand Ploner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Johannes Zacherl
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Friedrich Wrba
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Friedrich Längle
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Evelyne Bareck
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wolfgang Eisterer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Thomas Kühr
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Wolfgang Schima
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Michael Häfner
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Thomas Brodowicz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas Brodowicz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ploner, F., Zacherl, J., Wrba, F. et al. Gastrointestinal stromal tumors: Recommendations on diagnosis, therapy and follow-up care in Austria. Wien Klin Wochenschr 121, 780–790 (2009). https://doi.org/10.1007/s00508-009-1278-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00508-009-1278-4

Keywords

Search

Navigation